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RESEARCH
Ezh2-dCas9 and KRAB-dCas9 enable 
engineering of epigenetic memory 
in a context-dependent manner
Henriette O’Geen1* , Sofie L. Bates1, Sakereh S. Carter1, Karly A. Nisson2, Julian Halmai3, Kyle D. Fink3, 
Suhn K. Rhie2, Peggy J. Farnham2 and David J. Segal1
Abstract 
Background: Rewriting of the epigenome has risen as a promising alternative to gene editing for precision medi-
cine. In nature, epigenetic silencing can result in complete attenuation of target gene expression over multiple 
mitotic divisions. However, persistent repression has been difficult to achieve in a predictable manner using targeted 
systems.
Results: Here, we report that persistent epigenetic memory required both a DNA methyltransferase (DNMT3A-
dCas9) and a histone methyltransferase (Ezh2-dCas9 or KRAB-dCas9). We demonstrate that the histone methyltrans-
ferase requirement can be locus specific. Co-targeting Ezh2-dCas9, but not KRAB-dCas9, with DNMT3A-dCas9 and 
DNMT3L induced long-term HER2 repression over at least 50 days (approximately 57 cell divisions) and triggered an 
epigenetic switch to a heterochromatic environment. An increase in H3K27 trimethylation and DNA methylation was 
stably maintained and accompanied by a sustained loss of H3K27 acetylation. Interestingly, substitution of Ezh2-
dCas9 with KRAB-dCas9 enabled long-term repression at some target genes (e.g., SNURF) but not at HER2, at which 
H3K9me3 and DNA methylation were transiently acquired and subsequently lost. Off-target DNA hypermethylation 
occurred at many individual CpG sites but rarely at multiple CpGs in a single promoter, consistent with no detectable 
effect on transcription at the off-target loci tested. Conversely, robust hypermethylation was observed at HER2. We fur-
ther demonstrated that Ezh2-dCas9 required full-length DNMT3L for maximal activity and that co-targeting DNMT3L 
was sufficient for persistent repression by Ezh2-dCas9 or KRAB-dCas9.
Conclusions: These data demonstrate that targeting different combinations of histone and DNA methyltransferases 
is required to achieve maximal repression at different loci. Fine-tuning of targeting tools is a necessity to engineer 
epigenetic memory at any given locus in any given cell type.
Keywords: Epigenetic memory, Epigenome editing, CRISPR–dCas9, Ezh2, Epigenetics, Histone methylation, DNA 
methylation, Chromatin, Gene expression, Off-target effects
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Introduction
Epigenome engineering, the targeted rewriting of epige-
netic information, has risen as a promising alternative 
to cleavage-dependent gene editing, but our knowledge 
related to engineering long-term epigenetic memory is 
limited (reviewed in [1, 2]). Distinct epigenomic profiles 
define cellular identity among cells carrying the same 
genetic information. Chromatin organization is tightly 
regulated during development and is critical for estab-
lishing and maintaining cell-type-specific transcriptional 
programs forming the foundation of cellular memory. 
Acquired epigenetic alterations can lead to aberrant epi-
alleles implicated in diseases, such as cancers, cardiovas-
cular disease and mental disorders [3, 4].
Epigenetic marks, including posttranslational histone 
modifications and DNA methylation, have been profiled 
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across hundreds of human tissues, and cells have pro-
vided maps of unique cellular identity [5, 6]. Transcrip-
tional activity has been associated with certain epigenetic 
marks. For example, repressed genes have been asso-
ciated with posttranslational modifications (PTM) on 
histone tails including trimethylation of lysines 9 and 
27 on histone H3 (H3K9me3 and H3K27me3, respec-
tively) and ubiquitination of histone H2A on lysine 119 
(H2AK119u1) [7–9]. Although these are all hallmarks of 
a repressive chromatin state, they mark distinct regions 
of the genome. H3K9me3 is typically present at consti-
tutive heterochromatin associated with repeat regions 
of the genome, while H3K27me3 and H2AK119u1 mark 
facultative heterochromatin and the inactive X chromo-
some and play a critical role at developmentally regu-
lated genes [8, 10–13]. The patterns of histone marks 
and chromatin-associated proteins define distinct tran-
scriptional states that are established and maintained 
through a dynamic interplay of histone readers, writers 
and erasers creating a positive feedback loop. For exam-
ple, trimethylation of H3K27 is mainly maintained by one 
enzyme, namely Enhancer of Zeste Homolog 2 (EZH2). 
EZH2 is the catalytic subunit of the Polycomb Repressive 
Complex 2 (PRC2), which also contains SUZ12 and EED 
[14, 15]. EED mediates PRC2 binding to H3K27me3 and 
is required for the propagation of H3K27me3 domains, 
suggesting a mechanism for the inheritance of the 
H3K27me3 mark through cell division [8]. DNA methyla-
tion on carbon 5 of cytosine (5mC) in promoter regions 
has also been associated with gene repression [16, 17]. 
DNMT3A and DNMT3B provide de novo DNA meth-
ylation in conjunction with the non-catalytic DNMT3L 
binding partner, while maintenance of DNA methyla-
tion is provided by DNMT1. Heterochromatin marked 
by both H3K9me3 and 5mC is bound by the KAP1/
SETDB1(ESET) co-repressor complex, which is recruited 
by the Krueppel-associated box (KRAB) domain [18, 
19]. The KAP1/SETDB1 complex also recruits HP1 and 
DNMT3A.
Several tools have been developed to repress or acti-
vate gene expression or modulate epigenetic marks at a 
defined locus. These epigenetic editing tools consist of a 
DNA binding module and an epigenetic effector domain. 
The easily programmable CRISPR/Cas9 system is the 
method of choice for precise genome targeting. Two sin-
gle amino acid changes converts the Cas9 nuclease into a 
catalytically inactive or “dead” Cas9 (dCas9), which asso-
ciates with its DNA target sequence through simple base 
pairing of a short RNA guide to which it is bound [20]. 
Epigenetic effector domains have been fused to dCas9 
(epi-dCas9), which allow precise targeting of promoter 
and/or enhancer regions to alter associated epigenetic 
marks, typically with the readout of gene activation or 
repression [2]. The KRAB domain is the most commonly 
used repression domain [20–22]. Because of its potent 
repressive capacity, dCas9-KRAB fusions are now used 
for high-throughput gene discovery screens [23, 24]. 
However, the repressive activity of KRAB-dCas9 fusions 
at the target locus is only of transient nature and tran-
scription is re-established once the transcriptional modi-
fier protein is depleted [25, 26]. For example, we have 
previously reported that targeting the HER2 (ERBB2) 
gene with epi-dCas9 fusions to KRAB, FOG1, Ezh2 and 
DNMT3A can induce transient repression of HER2 gene 
expression in HCT116 cells [26]. As expression of epi-
dCas9 subsided, HER2 expression was re-established to 
original levels.
Unlike the forced epigenetic changes described above, 
natural epigenetic changes often lead to robust and per-
sistent changes in gene expression, sometimes lasting 
over the lifetime of an individual. Here, we have inves-
tigated the parameters required to achieve persistent 
epigenetic silencing of gene expression. Tools to engi-
neer epigenetic memory are starting to emerge, but our 
understanding of the requirements for a persistent epige-
netic switch is in its infancy. Others have reported [25, 
27] that persistent gene repression requires the combina-
tion of KRAB (recruiting a complex containing the his-
tone methylase SETDB1) and a DNA methyltransferase. 
However, we observed that this combination is not effec-
tive in inducing long-term epigenetic silencing at any 
given locus. In this study, we demonstrate that the com-
bination of DNA methylation with a different histone 
methyltransferase, namely Ezh2, is necessary to induce a 
persistent epigenetic switch and long-term repression of 
the HER2 oncogene in HCT116 cells. Global methylation 
analysis in cells in which Ezh2-dCas9 and KRAB-dCas9 
was transiently targeted to the HER2 locus revealed 
hypermethylation of many individual CpG probes 
throughout the genome even 3 weeks after exposure, but 
rarely resulted in differentially hypermethylated regions 
(DMRs) of > 3 CpGs within gene promoters. Notably, 
hypermethylation of > 3 promoter CpGs did not result in 
a change of transcription at the examined off-target loci. 
However, close investigation of the chromatin state at the 
HER2 locus revealed that long-term repression facilitated 
by Ezh2 and DNA methylases corresponds with an engi-
neered and stably maintained heterochromatic environ-
ment of H3K27 trimethylation and DNA methylation. In 
fact, DNA methylation expanded beyond the genomic 
target sites, leading to a 1.25-kb hypermethylated region 
at the HER2 promoter. We extended our evaluation of 
inducing long-term repression to two loci in different 
mouse and human cell lines. We demonstrated that DNA 
methylation improved long-term silencing by KRAB-
dCas9, but was absolutely required for robust long-term 
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repression by Ezh2-dCas9. In summary, our data dem-
onstrate that we can induce a persistent locus-specific 
epigenetic switch, but different histone and DNA methyl-
transferases are required to achieve long-term repression 
at different loci and/or in different cell types.
Materials and methods
Plasmids
Plasmids expressing dCas9 fusions with KRAB, Ezh2, 
DNMT3A effector domains, as well as the dCas9 clon-
ing vector without any effector domain, have previously 
been described [26] and are available through Addgene 
(KRAB-dCas9 #112195 Ezh2-dCas9 #100086, dCas9 
#100091). The DNMT3L expression plasmid pCDNA-
DNMT3L was a kind gift from Dr. Fred Chedin [28]. 
DNMT3A-dCas9 (Addgene #100090) and pCDNA-
DNMT3L are abbreviated in this study to D3A-dCas9 
and D3L, respectively. DNMT3L was amplified from 
pCDNA-DNMT3L with overhangs for Gibson clon-
ing into a KpnI- or NheI-digested dCas9 cloning vec-
tor, resulting in D3L-dCas9 (Addgene) and dCas9-D3L 
(Addgene), respectively. Protein sequences are shown 
in Additional file  1: Figure S1. A plasmid expressing a 
hybrid of mouse Dnmt3a and human DNMT3L fused 
to dCas9 (dCas9-D3a3L) was a kind gift from Dr. Albert 
Jeltsch [29]. The gRNA cloning vector, plasmid # 41824, 
was obtained from Addgene [30], and the 19-bp gRNA 
target sequences were selected within 500 bp of each rel-
evant gene promoter using the online tool CHOPCHOP 
v2 [31]. Each gRNA sequence was cloned as G-N19 into 
the AflII-linearized plasmid, as previously described 
[26]. The gRNA sequences used to create target-specific 
vectors are listed in Additional file 2: Table S1. Plasmids 
expressing 1xMCP-effector fusions were generated by 
cloning effector domains into NcoI- and ClaI-digested 
UBC-NLS-HA-2XMCP-tagRFPt [32] Addgene plasmid 
#64541). 2xMCP-effector fusion plasmids were created 
using XbaI- and ClaI-digested UBC-NLS-HA-2XMCP-
tagRFPt. KRAB and Ezh2 effector domains were ampli-
fied with overhangs from KRAB-dCas9 and Ezh2-dCas9 
and cloned using the Gibson method into the appropri-
ately cut vector. Protein sequences for 2xMCP-KRAB 
(Addgene) and 2xMCP-Ezh2 (Addgene) are shown in 
Additional file 1: Figure S1. MS2-gRNA expressing plas-
mids were created using the sgRNA(MS2) backbone [33], 
Addgene plasmid #61427) following the authors’ instruc-
tions (http://sam.genom e-engin eerin g.org/proto cols/). 
MS2-gRNA sequences are listed in Additional file  2: 
Table S1.
Cell culture and transfections
HCT116 cells (ATCC #CCL-247) were maintained 
in McCoy’s 5A medium supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin. 
LNCaP cells (ATCC #CRL-1740) were grown in RPMI-
1640 medium supplemented with 10% FBS and 1% peni-
cillin/streptomycin. 3T3 cells were grown in Dulbecco’s 
modified Eagle’s medium supplemented with 10% FBS 
and 1% penicillin/streptomycin. Neuro2A (ATCC #CCL-
131) cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf 
serum (FCS). All cells were grown at 37 °C under 5%  CO2. 
Cells of 60–70% confluency were transfected using Lipo-
fectamine 3000 (Life Technologies) following the manu-
facturer’s instructions. Transfections for RNA extraction 
and FACS sorting were performed in 12-well plates using 
625  ng individual or combinations of dCas9 expression 
vector, 500  ng of equimolar pooled gRNA expression 
vectors. Transfections for MS2-based recruitment were 
carried out using the same protocol with the follow-
ing plasmid amounts: 337  ng MS2-gRNA pool, 450  ng 
dCas9 expression vector and 338 ng MCP-effector plas-
mid. All experiments were co-transfected with 125  ng 
of puromycin-resistant plasmid pBABE-puro to select 
for transfected cells. Transfection medium was replaced 
24  h post-transfection with growth medium containing 
3-µg/ml puromycin to enrich for transfected cells. After 
72 h of puromycin selection, cells for RNA isolation were 
stored at 4 °C in RNAlater (Ambion) or collected for sort-
ing by flow cytometry. To assay for persistent repression, 
media was switched to standard growth media 4  days 
after transfection. For ChIP assays, cells were plated in 
10-cm culture dishes and transfection followed the same 
protocol except that reagents were scaled up accordingly.
Flow cytometry
Transfected HCT116 cells were assayed by flow 
cytometry after 72-h puromycin selection (96  h after 
transfection). For flow cytometry collection of the 
HER2-negative cell population, cells were harvested 
from two independent biological replicates, washed 
once in PBS, and resuspended in 1% bovine serum 
albumin (BSA) in PBS. After adding 3  µl APC-con-
jugated antihuman CD340 (erbB2/HER-2) antibody 
(Biolegend #324408), cells were incubated for 30  min 
at 4  °C. Labeled cells were washed once and resus-
pended in 1% BSA in PBS. Cell sorting was performed 
using an Astrios EQ cell sorter (Beckman Coulter) at 
the UC Davis Flow Cytometry Shared Resource Core. 
Untreated HCT116 control cells were used to deter-
mine the APC signal for HER2-expressing cells, while 
unlabeled cells were used to determine the sorting gate 
for HER2-negative cells. Four days after combinato-
rial epi-dCas9 transfections, HER2-negative cells were 
collected and replated using standard media. Cells 
were harvested at indicated time points, dependent on 
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cells reaching ~ 80% confluency. Cells were expanded 
in 24-well dishes for RNA isolation (5  days, 14  days, 
23  days, 39  days, 44  days and 50  days) and in 6-well 
dishes for DNA methylation analysis (10 days, 17 days 
and 24  days) and Western blot analysis (40  days). For 
ChIP assays (24 days), cells were plated in 10-cm dishes.
RNA extraction and reverse‑transcription quantitative PCR 
(RT‑qPCR)
Cells for RNA isolation were stored in RNAlater 
(Ambion) at 4  °C for up to 1  week. RNAlater was 
removed, and total RNA was isolated using the RNeasy 
Plus RNA isolation kit (Qiagen). RNA was reverse-tran-
scribed using the SuperScript VILO MasterMix (Invit-
rogen). RT-qPCR was performed in triplicate using 2 × 
iQ SYBR mix (Bio-Rad) with the CFX384 Real-Time 
System C1000 Touch system (Bio-Rad). Gene expression 
analysis was performed with GAPDH as a reference gene 
using at least three biological replicates and the follow-
ing primer sequences: human HER2 primers (HER2-F 
5′-GGG AAA CCT GGA ACT CAC CT-3′; HER2-R 5′-GAC 
CTG CCT CAC TTG GTT GT-3′), SNURF (human) prim-
ers (SNURF-F 5′-CTG TCT GAG GAG CGG TCA GT-3′; 
SNURF-R 5′-CAG GTA CTT GCT GCT GCT GA-3′), 
human GAPDH primers (GAPDH-F 5′-AAT CCC ATC 
ACC ATC TTC CA-3′; GAPDH-R 5′-CTC CAT GGT GGT 
GAA GAC G-3′), mouse Snurf primers (mSnurf-F 5′-TTG 
GTT CTG AGG AGT GAT TTGC-3′; mSnurf-R 5′-CCT 
TGA ATT CCA CCA CCT TG-3′), and mouse Gapdh 
primers (mGapdh-F 5′-TGA CCA CAG TCC ATG CCA 
TC-3′; mGapdh-R 5′-GAC GGA CAC ATT GGG GGT 
AG-3′). Primer sequences used for RT-qPCR of potential 
off-targets are listed in Additional file 2: Table S1. Rela-
tive target gene expression was calculated as the differ-
ence between the target gene and the GAPDH reference 
gene (dCq = Cq[target] − Cq[GAPDH]). Gene expression 
results are indicated as fold change to a reference sam-
ple (usually dCas9 without any effector domain), using 
the ddCq method. A one-way ANOVA (ANalysis Of 
VAriance) with post hoc Tukey HSD (honestly significant 
difference) or Dunnett’s test was used to determine sta-
tistical significance for different epi-dCas9 treatments.
Western blot analysis
Transfected HER2-negative cells were collected by flow 
cytometry 4  days after transfection and harvested for 
protein extraction 40  days after transfection. Cells were 
lysed in 1 × RIPA buffer (Millipore) supplemented with 
protease inhibitor cocktail (Roche), and protein concen-
trations were determined by Bradford assay (Bio-Rad). 
For Western blots, 30  μg of protein was separated on a 
4–15% TGX gel (Bio-Rad) with Tris/glycine/sodium 
dodecyl sulfate buffer. Protein was subsequently trans-
ferred onto a nitrocellulose membrane, and protein 
loading was evaluated by Ponceau S stain. The mem-
brane was rinsed with deionized water and incubated in 
blocking solution (5% nonfat dry milk in TBST; 50 mM 
Tris, 150 mM NaCl, 0.1% Tween-20) for 30 min at room 
temperature. Membranes were incubated with primary 
antibody in blocking solution at 4 °C overnight. We used 
Anti-c-ErbB2/c-Neu (Ab-3) mouse mAb (3B5) antibody 
at 1:1000 dilution (SIGMA #OP15). After three 10-min 
washes with TBST, the membrane was incubated with 
horseradish peroxidase-conjugated antimouse secondary 
antibody (1:2000 dilution in TBST) for 45  min at room 
temperature. After three more washes in TBST, proteins 
were visualized with Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare) using the 
ChemiDoc XRS Imaging System (Bio-Rad).
Chromatin immunoprecipitation (ChIP) and ChIP‑qPCR
HCT116 cells were transfected with D3A-dCas9/D3L 
and either KRAB-dCas9 or Ezh2-dCas9 and three 
gRNAs targeting the HER2 promoter. Control cells were 
transfected with dCas9 and the same three gRNAs. For 
transient repression timepoints, cells were cross-linked 
4  days after transfection and growth in puromycin-
containing media. For persistent repression timepoints, 
cells were sorted as described above and dCas9 control 
cells were cross-linked 24 days after transfection. Cross-
linking was carried out in 1% formaldehyde for 10  min 
at room temperature and was stopped with 0.125 M gly-
cine. Cross-linked cells were lysed with ChIP lysis buffer 
(5 mM PIPES pH8, 85 mM KCl, 1% Igepal) with a pro-
tease inhibitor (PI) cocktail (Roche). Nuclei were col-
lected by centrifugation at 2000  rpm. for 5  min at 4  °C 
and lysed in nuclei lysis buffer (50 mM Tris pH8, 10 mM 
EDTA, 1% SDS) supplemented with PI cocktail. Chroma-
tin was fragmented using the Bioruptor 2000 (Diagen-
ode) and diluted with 5 vol RIPA buffer (50 mM Tris pH 
7.6, 150 mM NaCl, 1 mM EDTA pH8, 1% Igepal, 0.25% 
deoxycholic acid). ChIP enrichment was performed by 
incubation with 3  µg H3K9me3 antibody (Diagenode 
C15410056), 2 µg H3K27me3 antibody (MP07–449), 2 µg 
H3K27ac antibody (Active Motif #39133) or 2 µg normal 
rabbit IgG (Abcam ab46540) for 16  h at 4  °C. Immune 
complexes were bound to 20  µl magnetic protein A/G 
beads (ThermoFisher) for 2 h at 4 °C. Beads were washed 
2 × with RIPA and 3 × with ChIP wash buffer (100 mM 
Tris pH8, 500 mM LiCl, 1% deoxycholic acid). The final 
wash was performed in ChIP wash buffer with 150 mM 
NaCl. Cross-links were then reversed by heating beads 
in 100 µl ChIP elution buffer (50 mM  NaHCO3, 1% SDS) 
overnight at 65  °C, and DNA was purified using the 
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QIAquick PCR Purification Kit (Qiagen). qPCR was per-
formed with 2 × SYBR FAST mastermix (KAPA Biosys-
tems) using the CFX384 Real-Time System C1000 Touch 
Thermo Cycler (Bio-Rad). HER2 ChIP amplification 
primers are as follows: HER2-ChIP-F (5′-TTG GAA TGC 
AGT TGG AGG GG-3′) and HER2-ChIP-R (5′-GGT TTC 
TCC GGT CCC AAT GG-3′). ChIP enrichment was cal-
culated relative to input samples using the dCq method 
(dCq = Cq[HER2-ChIP] − Cq[input]). Statistical signifi-
cance was determined by Student’s t test.
ChIP‑sequencing and data analysis
Each entire ChIP sample was used to prepare Illumina 
sequencing libraries using the KAPA Hyper Prep Kit 
(Roche) and NEXTflex DNA barcodes (BIOO Scientific). 
Illumina sequencing libraries were pooled and sequenced 
using the HiSeq 4000 platform (Illumina) at the UC Davis 
DNA Technologies Sequencing Core. Short sequence 
reads (SR50) were aligned to the hg19 genome assembly 
using using BWA [34], and data were preprocessed using 
the ENCODE3 ChIP-seq pipeline (https ://www.encod 
eproj ect.org/chip-seq/). ChIP-seq peaks were called 
using MACS2 [35] from each replicate first, and then, 
reproducible peaks were selected using the naïve overlap 
tool, as suggested in the ENCODE3 ChIP-seq standards 
document (https ://www.encod eproj ect.org/pages /pipel 
ines/) and previously described [36]. To find reduced 
H3K27ac ChIP-seq promoter peaks in cells treated with 
Ezh2 plus D3A and D3L compared to dCas9 control, we 
selected top 15  k robust reproducible peaks from each 
dataset. H3K27ac peaks only found in the dCas9 con-
trol were identified by overlap analysis with treated cells 
using bedtools (https ://githu b.com/arq5x /bedto ols2). 
Lastly, peaks located in promoter regions (1-kb windows 
of transcription start sites) of protein coding genes (Gen-
code version 28, https ://www.genco degen es.org) were 
identified (n = 469 peaks). Using the DiffBind R package 
[37], ChIP-seq signals were normalized across samples 
and fold change of reduced peaks was calculated using 
average signal values (Additional file 6: Table S2). ChIP-
seq data have been submitted to the Gene Expression 
Omnibus (GEO) and are available under accession num-
ber GSE123882.
Analysis of methylation by bisulfite conversion
Genomic DNA from biological replicates was iso-
lated using the Quick-DNA Miniprep Kit (ZYMO), and 
bisulfite conversion was performed starting with 500 ng 
genomic DNA with the EZ DNA Methylation-Gold 
Kit (ZYMO) following the manufacturer’s instructions. 
Bisulfite-Sequencing PCR primers were designed using 
MethPrimer [38] (BSS-HER2-F 5′-GGA GGG GGT AGA 
GTT ATT AGT TTT T-3′ and BSS-HER2-R 5′- CAC CTC 
CTC CTT CTC CTA TAA TTA AA-3′); 100  ng bisulfite 
converted DNA was used for PCR amplification with 
ZymoTaq polymerase (ZYMO), and the 229-bp PCR 
product was purified with the QIAquick PCR Purifica-
tion Kit (Qiagen). Amplicons were subcloned into the 
pCR2.1-TOPO TA vector using the TOPO TA cloning 
kit (ThermoFisher) and transformed into NEB5α com-
petent cells (NEB). Individual clones were subjected to 
Sanger sequencing (Genewiz), and methylation status of 
11 CpGs immediately upstream of the HER2 TSS (hg19, 
chr17:37,856,035–37,856,263) was determined. The same 
amplicons from bisulfite converted DNA were sent for 
high-throughput sequencing at the CCIB DNA Core 
Facility at Massachusetts General Hospital (Cambridge, 
MA). Sequencing data were processed using FLASH2 
to merge overlapping paired-end reads and single long 
reads were then demultiplexed using FASTX barcode 
splitter by matching barcodes at the beginning or end of 
the sequences, with one mismatch allowed. Methylation 
levels were of bisulfite-treated sequencing reads and were 
analyzed with Bismark [39] using a bisulfite reference and 
default settings.
Global DNA methylation analysis
HCT116 cells were transfected with D3A-dCas9/D3L 
and either KRAB-dCas9 or Ezh2-dCas9 and three 
gRNAs targeting the HER2 promoter. Each replicate 
(n = 2) was performed as an entirely separate trans-
fection experiment. Transfected cells were sorted by 
flow cytometry as described above and genomic DNA 
was extracted. Control cells were transfected with 
three HER2 gRNAs and dCas9 (no effector domain). 
Genomic DNA from sorted and control cells was 
isolated 17 and 24  days after transfection using the 
Quick-gDNA MiniPrep kit (ZYMO). The Infinium 
Human MethylationEPIC BeadChip (Illumina) was 
used to analyze global DNA methylation. Genomic 
DNA was bisulfite converted and EPIC DNA methyla-
tion array data were processed in the USC Molecular 
Genomics Core; the methylation status of over 850,000 
CpG probes was reported. For each probe, methyl-
ated (M) and unmethylated (U) signal intensities were 
recorded and the beta value (M/(M + U)) was deter-
mined for each probe. Samples were normalized (back-
ground corrected) using the ‘noob’ function in the 
minfi software program in R computing language. All 
downstream analysis was conducted using the hg19/
GRCh37 human genome assembly. To identify hyper-
methylated probes located in promoter regions, we 
first selected probes located in promoter regions (Illu-
mina MethylationEPIC Manifest RefGene annotation 
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5′UTR, TSS200 and TSS1500) (511,700 CpG probes), 
and then, probes showing increased DNA methylation 
levels in treated cells (KRAB + D3A + D3L 17  days, 
Ezh2 + D3A + D3L 17  days, and Ezh2 + D3A + D3L 
24  days) compared to dCas9 control samples (mean 
beta value difference cut off 0.2) were selected (223, 
2966, 2018 probes for KRAB + D3A + D3L 17  days, 
Ezh2 + D3A + D3L 17  days, and Ezh2 + D3A + D3L 
24  days, respectively; Additional file  9: Table  S3). On 
the other hand, hypomethylated probes located in 
promoter regions were identified by selecting probes 
showing decreased DNA methylation levels in treated 
samples compared to control samples (mean beta value 
difference cut off 0.2). Genes that include more than 
3 hypermethylated promoter probes were selected to 
generate Venn diagrams. EPIC array data have been 
submitted to the Gene Expression Omnibus (GEO) 
and are available under accession number GSE123830.
Results
Ezh2‑dCas9, but not KRAB‑dCas9, enables long‑term 
silencing by creating a persistent heterochromatin 
environment at the HER2 locus
We have previously created a toolbox of dCas9 fusions 
with epigenetic effector domains (epi-dCas9), which can 
deposit their respective epigenetic marks at the endog-
enous HER2 target site in HCT116 cells when trans-
fected individually [26]. DNMT3A-dCas9 (D3A-dCas9) 
establishes 5C DNA methylation, Ezh2[FL]-dCas9 
(Ezh2-dCas9) establishes H3K27 trimethylation, and 
KRAB-dCas9 induces H3K9 trimethylation at the target 
site (Fig.  1a). Individual epi-dCas9 fusions were capable 
of transient HER2 repression, but they failed to induce 
long-term repression. Although reports have emerged 
that a combination of the KRAB repressor domain and 
DNA methyltransferases is required to engineer epige-
netic memory [25, 27], we were unable to use this com-
bination to engineer long-term repression at the HER2 
locus in HCT116 cells [26]. In this study, we aim to gain a 
better understanding of the requirements to stably engi-
neer epigenetic memory at different loci. First, we com-
pared combinatorial treatment of DNA methylation with 
either KRAB or with the histone methyltransferase Ezh2 
and the effect on long-term repression and establishment 
and maintenance of a repressive epigenetic state. For this 
purpose, HCT116 cells were co-transfected with either 
Ezh2-dCas9 or KRAB-dCas9 cocktail, plus D3A-dCas9 
and D3L, and three gRNAs targeting the HER2 gene 
promoter (Fig. 1a). To more easily monitor gene expres-
sion over time, we took advantage of the transmem-
brane properties of the HER2 protein and employed flow 
cytometry to collect cells with no/low APC-HER2 fluo-
rescence (HER2−) 4 days after transfection (Fig. 1b). On 
average, 14% of the cells from three biological replicates 
were HER2− after exposure to the Ezh2-dCas9 cocktail 
and 28% were HER2− after treatment with the KRAB 
Fig. 1 Hit-and-run epigenetic editing by Ezh2-dCas9, but not KRAB-dCas9, with targeted DNA methylation establishes and maintains a local 
heterochromatic environment. a Schematic representation of epi-dCas9. dCas9 fusions to effector domains (ED) contained N-terminal and 
C-terminal nuclear localization domains (NLSs), as well as an N-terminal 3XFLAG epitope tag with a 15-aa linker [(GGS)5] separating dCas9 and 
the EDs. Effector domains KRAB, Ezh2 and DNMT3A with domains are shown next to epigenetic marks they induce. A detailed view around the 
human HER2 promoter region shows an annotated CpG island (green bar), gRNAs targeting HER2 promoter region (blue boxes) and the regions 
interrogated by bisulfite cloning (gray bar) and ChIP-qPCR (black bar). The transcription start site (TSS) is indicated. UCSC browser tracks of DNAse1 
hypersensitivity and H3K27ac ChIP-seq enrichment at the HER2 locus (human genome assembly hg19) are also shown. b Diagram of experimental 
design to assay for long-term repression using flow cytometry to select for low HER2 expression (HER2−) 4 days after transient transfection assays. 
Relative epi-dCas9 expression was determined by RT-qPCR in HCT116 cells after co-transfection of plasmids expressing dCas9,KRAB-dCas9 and 
Ezh2-dCas9 with three gRNAs targeted to the HER2 promoter (Dunnett’s test P < 0.001; n = 3 independent experiments per epi-dCas9 fusion; 
mean ± SEM). Representative flow cytometry data for HER2 expression in HCT116 cells treated with plasmids expressing Ezh2 + D3A + D3L 
(Ezh2-dCas9, D3A-dCas9 and overexpressed D3L) or KRAB + D3A + D3L (KRAB-dCas9, D3A-dCas9 and overexpressed D3L) in the presence of three 
gRNAs targeting the HER2 promoter. HER2− cells collected are indicated. Untreated control to identify HER2+ population is shown on the left. c 
Long-term repression of HER2 mRNA levels in HER2− cells was monitored for 50 days using RT-qPCR after co-transfection of plasmids expressing 
the indicated epi-dCas9 fusions and three gRNAs targeted to the HER2 promoter (n = 3 independent experiments each; mean ± SEM). d Average 
methylation levels were determined by bisulfite cloning at the HER2 promoter 10 days after transfection with the indicated Ezh2-dCas9 and 
KRAB-dCas9 cocktails or dCas9 (no effector domain). Each line represents a single clone, filled and empty circles represent a single methylated 
or unmethylated CpG, respectively. Average % methylation is indicated for each treatment. e Methylation level of CpG probes along 7 kb of the 
HER2 locus 17 days after HCT116 cells were co-transfected with indicated epi-dCas9 and three gRNAs targeting the HER2 promoter. CpG Island 
is shown in green. f Transient (4 days) and persistent (24 days) histone methylation was determined by ChIP-qPCR at the HER2 promoter in 
HCT116 cells co-transfected with either dCas9 with no ED or the indicated epi-dCas9 treatment cocktail and three gRNAs targeted to the HER2 
promoter (Student’s t test, *P < 0.05, ***P < 0.001; n = 2–4; mean ± SEM). Due to higher cell number required for ChIP-qPCR, cells were cross-linked 
immediately after puromycin selection (4 days); sort for HER2− cells by FACS was omitted. H3K27me3 and H3K9me3 ChIP enrichment was assayed 
for Ezh2 + D3A + D3L and KRAB + D3A + D3L, respectively and compared to dCas9 with no ED. Decrease of H3K27ac enrichment was measured by 
ChIP-qPCR at the HER2 promoter in HCT116 at 4 and 24 days after co-transfection with three gRNAs targeted to the HER2 promoter and dCas9 with 
no ED or the epi-dCas9 treatment cocktail Ezh2 + D3A + D3L (Student’s t test, **P < 0.01, *P < 0.05; n = 2–3; mean ± SEM)
(See figure on next page.)
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cocktail (Fig.  1b). Thus, the stronger transient repres-
sive activity of KRAB-dCas9 was reflected in the higher 
number of HER2− cells, indicating that this method can 
be used to monitor HER2 gene expression (repression 
of HER2 expression also leads to persistent reduction in 
HER2 protein; see Additional file 3: Figure S2A). HER2− 
cells were then maintained without selection for 50 days 
after transfection. Unsorted cells transfected with dCas9 
(no effector domain) were grown in parallel and used as 
a control. Time points for individual experiments were 
determined by expansion of sorted cells to 80% conflu-
ency (see "Materials and methods"). As expected, trans-
fected epi-dCas9 fusions were transiently expressed at 
high levels 5  days after transfection, but expression of 
dCas9 fusions was no longer detectable  12  days after 
transfection (Fig.  1b). Ezh2-dCas9 in combination with 
D3A-dCas9 and D3L produced persistent twofold repres-
sion for the entire 50-day period, supporting the hypothe-
sis that a repressive state was established and maintained 
through approximately 57 mitotic cell divisions (doubling 
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time ~ 21  h) (Fig.  1c). Although KRAB-dCas9 together 
with D3A-dCas9 and D3L initially repressed HER2 
expression by 3.3-fold, repression was lost and normal 
HER2 expression was re-established by day 14 after trans-
fection. Although we sorted and expanded HER2− cells, 
we observed persistent repression of only twofold. This 
could either represent partial repression in individual 
cells or result from a bimodal population where a subset 
of cells maintained the HER2− state and another subset 
regained HER2 expression. We performed FACS analy-
sis to evaluate the HER2 protein level in cells 54  days 
post-transfection (50  days after the initial sort). FACS 
analysis demonstrates all-or-none maintenance of silenc-
ing events (Additional file  3: Figure S2B). We observed 
31% HER2− cells in the population treated with Ezh2-
dCas9, D3A-dCas9 and D3L, while 2% of cells remained 
HER2− after exposure to the KRAB-dCas9 cocktail. No 
HER2− cells were present after treatment with dCas9 (no 
effector).
We then investigated whether the persistent change in 
HER2 expression was accompanied by a change in the 
chromatin environment at the HER2 promoter. We inter-
rogated a 229-bp region in the HER2 promoter (Fig. 1a) 
by bisulfite sequencing to determine the methylation 
status in HER2− cells 10 days after treatment with Ezh2-
dCas9 or KRAB-dCas9 cocktail (plus D3A-dCas9 and 
D3L) and three gRNAs targeting the HER2 gene pro-
moter. Treatment with KRAB-dCas9 cocktail resulted in 
39% methylation, while Ezh2-dCas9 facilitated treatment 
showed increased methylation of 54% (Fig. 1d). No meth-
ylation was observed in cells treated with dCas9 with no 
effector domain (Fig.  1d). We further wanted to inves-
tigate whether hypermethylation was associated with 
spreading of DNA methylation. We used the Illumina 
Infinium HumanMethylationEPIC (EPIC) array to inves-
tigate DNA methylation beyond the target site 17  days 
after treatment. Cells treated with Ezh2-dCas9/D3A-
dCas9 and D3L showed hypermethylation of all 12 CpGs 
in the HER2 promoter region and the promoter-prox-
imal 5′UTR region with an average methylation of 48% 
as compared to 7% in dCas9 control samples (Fig. 1e). In 
addition to the 416-bp nucleation site (spanned by the 
3 HER2 gRNAs), hypermethylation spread through the 
downstream CpG island, creating a 1.25-kb hypermeth-
ylated region (Fig. 1e). On the other hand, only a single 
HER2 promoter CpG was hypermethylated 17 days after 
treatment with KRAB-dCas9/D3A-dCas9 and D3L. The 
single hypermethylated CpG was located in the CpG 
island downstream of the gRNA target region and was 
not associated with HER2 gene repression (Fig. 1c). This 
suggests that higher initial methylation level (Fig.  1d) 
and/or spreading of DNA methylation (Fig. 1e) facilitated 
by Ezh2-dCas9 plus DNA methyltransferases enables 
persistence of a repressive chromatin state and thereby 
enables long-term epigenetic memory at the target locus.
We next determined whether co-targeting with Ezh2-
dCas9 or KRAB-dCas9 resulted in deposition and main-
tenance of the corresponding histone marks (H3K27me3 
and H3K9me3, respectively). Because cell number was 
limited after sorting for HER2− cells, we performed 
ChIP-qPCR on unsorted cells for the transient time 
point (4 days), but used the collected HER2− population 
(Fig.  1b) for the persistent time point (24  days). ChIP-
qPCR confirmed the presence of the expected histone 
marks 4 days after transfection (Fig. 1f ), when epi-dCas9 
was still present (see Fig.  1b). In addition, the 6.6-fold 
increase in H3K27 trimethylation at the HER2 promoter 
mediated by Ezh2-dCas9 was maintained at a similar 
level (4.7-fold) at 24 days after transfection (Fig. 1f ). On 
the other hand, KRAB-dCas9 initially triggered a sig-
nificant increase in H3K9 trimethylation (102-fold), but 
this epigenetic mark was completely lost 24  days after 
transfection; this loss corresponded to the loss of HER2 
repression. To determine whether the gain in the repres-
sive H3K27 methylation mark is accompanied by a loss 
of the active H3K27 acetylation mark, we performed 
H3K27ac ChIP-qPCR. Indeed, we observed a 1.4-fold 
decrease in H3K27ac 4  days after transfection, which 
was more pronounced (5.2-fold) 24  days after exposure 
to Ezh2-dCas9 plus D3A-dCas9 and D3L (Fig. 1f ). These 
data clearly demonstrate that targeting Ezh2-dCas9, 
D3A-dCas9 and D3L establishes and maintains a repres-
sive chromatin environment comprised of DNA and his-
tone methylation.
Long‑term silencing by combinatorial treatment 
with Ezh2‑dCas9 or KRAB‑dCas9 is locus specific
Co-targeting DNA methylation with Ezh2-dCas9, but 
not with KRAB-dCas9, stably silenced HER2 expres-
sion. We then wanted to investigate whether another 
locus that is readily silenced by a combination of 
KRAB-dCas9 with D3A-dCas9 and D3L also responds 
to combinatorial Ezh2-dCas9 treatment, or whether 
the two modes of action are mutually exclusive. For this 
purpose, we evaluated different combinations of epi-
dCas9 fusions using three gRNAs targeting the Snurf 
promoter in Neuro2A cells. Transient repression was 
measured 4  days post-transfection under puromycin 
selection to enrich for transfected cells, while persis-
tent repression was measured after cells were grown 
for an additional 10  days in puromycin-free media 
(Fig.  2a). Informed by our results (Fig.  1c) and previ-
ous reports [25, 26], we evaluated persistent silencing 
14  days after transfection. In addition to Ezh2-dCas9, 
we included dCas9-FOG [N + C], which deposits simi-
lar levels of H3K27 trimethylation when targeted to the 
Page 9 of 20O’Geen et al. Epigenetics & Chromatin           (2019) 12:26 
HER2 promoter [26]. All epi-dCas9 fusions were able 
to repress Snurf gene expression temporarily, rang-
ing from 2.6- to 14.2-fold downregulation (Fig.  2b). 
Importantly, dCas9 without any effector domain was 
also able to repress Snurf gene expression 3.6-fold. This 
effect, also known as CRISPR inhibition (or CRISPRi), 
is due to binding of dCas9 near the transcription start 
site and subsequent blocking access of endogenous fac-
tors required for transcription [40]. As expected, indi-
vidual epi-dCas9 fusions (KRAB-dCas9, Ezh2-dCas9, 
D3A-dCas9, dCas9-FOG [N + C]) could cause tran-
sient repression, but in each case Snurf gene expression 
was re-established by 14  days after transfection. The 
observed CRISPRi effect of dCas9 without an effec-
tor domain was also of transient nature. Long-term 
repression of the Snurf gene by KRAB-dCas9 required 
co-expression of both D3A-dCas9 and D3L (two-
fold; Fig.  2b). On the other hand, long-term repres-
sion of the Snurf gene by Ezh2-dCas9 was observed in 
combination with D3A-dCas9 (1.6-fold) or after com-
binatorial treatment with D3A-dCas9 and D3L (1.6-
fold). dCas9-FOG [N + C] by itself, or in combination 
with D3A-dCas9 and D3L, was not able to confer long-
term repression of the Snurf gene. Similar results were 
obtained when targeting the TRPM4 promoter in C42B 
cells (Additional file  4: Figure S3). Interestingly, these 
data demonstrate that targeted H3K27me3 deposition 
by dCas9-FOG [N + C] is not sufficient for long-term 
repression, even in the presence of targeted DNA meth-
yltransferase, while H3K27me3 deposition by Ezh2-
dCas9, in combination with targeted DNA methylation 
by D3A-dCas9 and overexpression of D3L, does lead to 
long-term repression of Snurf expression. This suggests 
that either interaction of the epigenetic effectors them-
selves (Ezh2 and D3A) or recruitment of PRC2 complex 
partners specific to Ezh2 is necessary for long-term 
repression.
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individually or in combination with D3A-dCas9 with or without simultaneous overexpression of DNMT3L (D3L). Snurf mRNA levels were 
compared to dCas9 with no ED (Tukey-test, *P < 0.05, **P < 0.01, n = 2–3; mean ± SEM). c Long-term repression (14 days) resulting from epi-dCas9 
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We next investigated whether simultaneous recruit-
ment of the histone methyltransferase Ezh2 and DNA 
methyltransferases is also required in other cell types. 
It has previously been shown that long-term repression 
by a targetable fusion with the KRAB repressor domain 
required simultaneous recruitment of the histone meth-
yltransferase DNMT3A and DNMT3L in some, but not 
all cell types tested [25]. We observed that KRAB-dCas9 
by itself was able to induce modest long-term repres-
sion of Snurf in 3T3 cells as well as SNURF and HER2 
in LNCaP cells. However, long-term silencing efficiency 
was increased when a combination of KRAB-dCas9, 
D3A-dCas9 and D3L was used (Fig.  2c). Efficient long-
term repression by Ezh2-dCas9 also required addition 
of D3A-dCas9 and D3L. We note that the combination 
of D3A-dCas9 and D3L with Ezh2-dCas9 or KRAB-
dCas9 induced comparable levels of long-term repres-
sion: Ezh2-dCas9 facilitated 1.9- and 2.2-fold repression, 
while KRAB-dCas9 established 1.8- and 1.7-fold repres-
sion of Snurf/SNURF expression in 3T3 and LNCaP cells, 
respectively. In LNCaP cells, addition of D3A-dCas9 and 
D3L to Ezh2-dCas9 or KRAB-dCas9 established 3.4- and 
1.9-fold persistent HER2 repression, respectively. Among 
the two loci tested in different mouse and human cell 
types, only the HER2 locus in HCT116 cells was resistant 
to long-term silencing by KRAB-dCas9 in combination 
with D3A-dCas9 and D3L. This demonstrates that differ-
ent combinations of targeted histone and DNA methyl-
transferases are required to achieve maximal repression 
at the same locus in different cell types or at different 
loci in the same cell type. Altogether, these data indicate 
that there are locus- and/or cell-type-specific require-
ments for the specific tools needed to silence an endog-
enous gene by targeted recruitment of histone and DNA 
methylases.
Genome‑wide H3K27ac analysis demonstrates 
that combinatorial Ezh2‑dCas9 treatment leads to loss 
of H3K27ac specific to the HER2 target promoter
We demonstrated that the targeted increase in the 
repressive histone mark H3K27me3 is associated with 
long-term loss of H3K27ac (Fig. 1f ), which is associated 
with distal regulatory regions and with gene promot-
ers [9]. Therefore, loss of H3K27ac in promoter regions 
can be used as an indicator for reduced expression. We 
performed ChIP-seq  24  days after transfection with 
either dCas9 (control) or Ezh2-dCas9 cocktail (includ-
ing D3A-dCas9 and D3L) to analyze H3K27ac signals 
genome-wide; comparisons of H3K27ac peaks showed 
strong correlation between biological replicates (Spear-
man’s ρ > 0.98; Additional file  5: Figure S4). Biological 
replicates were then combined, and the top 15,000 robust 
ChIP-seq peaks were called in control and combinatorial 
Ezh2-dCas9 treatment, independently (Additional file 6: 
Table S2). When we compared the robust peaks, 13,528 
(91%) of H3K27ac peaks found in the control treatment 
were also present in cells that received Ezh2-dCas9 in 
combination with D3A-dCas9 and D3L (Additional file 7: 
Figure S5A and S5B). As expected, a H3K27ac binding 
peak at the HER2 target site was only identified in con-
trol cells, but no robust binding signal was observed 
after combinatorial Ezh2-dCas9 treatment (Fig.  3a). 
We were interested whether other promoters showed 
similarly reduced levels of H3K27ac, which may indi-
cate loss of transcription of the associated gene. 1392 
H3K27ac peaks were only present in control cells, but 
not in cells treated with Ezh2-dCas9 cocktail. Among 
these control-specific peaks, only 469 H3K27ac binding 
peaks were localized within ± 1  kb of the transcription 
start site (TSS). H3K27ac binding enrichment at these 
469 TSS proximal regions was calculated after normali-
zation using DiffBindR program [37], and the change in 
H3K27ac binding signals between control and combina-
torial Ezh2-dCas9 treatment was calculated. Only 20 of 
the 469 promoter-proximal regions showed a more than 
twofold reduction in H3K27ac binding (Fig.  3b, Addi-
tional file  6: Table  S2). The strongest reduction, which 
was 3.7-fold, was observed at the HER2 target site with 
the H3K27ac peak centered in the proximal promoter 
(− 288  bp relative to TSS). ARHGEF19 and RNF128 
showed a reduction of 3.6- and threefold, respectively. 
The H3K27ac ChIP-seq signal was smaller at ARHGEF19 
and RNF128 (approximately half and a fourth, respec-
tively) than at the HER2 target promoter. It is noteworthy 
that among the 20 promoter binding peaks showing more 
than twofold reduction, H3K27ac ChIP-seq signal was 
highest at the HER2 promoter (Additional file  7: Figure 
S5C). If H3K27ac changes were due to off-target bind-
ing of epi-dCas9 fusions, one would expect an overlap 
with predicted Cas9 off-targets. We used Cas-OFFinder 
[41] to identify predicted Cas9 off-targets in the human 
genome with a ‘NGG’ PAM sequence and allowing up to 
three mismatches to each of the three HER2 gRNA target 
sequences. There were 3, 58 and 28 predicted off-target 
sites for HER2 gRNAs 1,2 and 3, respectively (Additional 
file  2: Table  S1). Using bedtools, we determined that 
there was no overlap between predicted off-target sites 
and the 469 TSS proximal regions that showed reduced 
H3K27ac binding. To determine whether changes in 
H3K27ac binding affect gene expression, we performed 
RT-qPCR of the top 10 promoters with reduced H3K27ac 
enrichment. We found that 4 out of the 10 genes (GBX1, 
ADCK5, BRINP3, CD8A) were either not expressed 
or not detectable by RT-qPCR in HCT116 cells. The 
remaining six gene promoters did not show a change in 
gene expression 23 days after transfection (Fig. 3c). Thus, 
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Fig. 3 Combinatorial treatment with Ezh2-dCas9, D3A-dCas9 and D3L establishes persistent DNA and histone methylation specifically at the HER2 
target locus. a UCSC browser snapshot of H3K27ac ChIP-seq enrichment at the HER2 locus (human genome assembly hg19). Browser tracks are 
shown for biological replicates 24 days after co-transfection with indicated epi-dCas9 cocktail and 3 gRNAs targeting the HER2 promoter (dCas9 
control in top two panels, Ezh2 + D3A + D3L treated cells in bottom two panels). Targeted HER2 promoter region containing H3K27ac peak is 
highlighted in yellow. RefSeq genes are indicated. b Scatterplot of the fold change of H3K27ac binding (-dCas9/Ezh2 + 3A + 3L) after co-targeting 
of Ezh2 + D3A + D3L (24 days) against peak center distance from the transcription start site (TSS). 469 H3K27ac binding peaks that are specific 
to the dCas9 control were plotted. Black dots represent gene promoters with a more than twofold reduction of H3K27ac binding. Reduction of 
H3K27ac binding at the HER2 promoter is indicated with a red dot. c RT-qPCR at six loci with reduced H3K27ac ChIP binding 23 days after treatment 
with Ezh2-dCas9/D3A-dCas9 plus D3L. Expression levels were calculated relative to GAPDH (Sidak’s multiple comparisons test, ***P < 0.001, n = 3; 
mean ± SEM). d Distribution of DNA methylation levels in promoter regions. Average DNA methylation levels of HCT116 cells co-transfected with 
plasmids expressing three gRNAs targeting the HER2 promoter, and epi-dCas9 cocktails expressing D3A-dCas9 and D3L with either KRAB-dCas9 
(KRAB + D3A + D3L) or Ezh2-dCas9 (Ezh2 + D3A + D3L) are plotted against control cells transfected with same gRNAs and dCas9 with no ED. 
Hypermethylated HER2 CpG probes in promoter regions are colored in red, all other differentially methylated promoter CpG probes are colored 
in black. Promoter regions encompass 1500 bp upstream of the TSS as well as the 5′UTR. e Frequency of hypermethylated CpG probes per gene. 
Gene promoters containing more than three hypermethylated probes are considered differentially methylated promoters. After treatment with 
Ezh2 + D3A + D3L the HER2 target promoter shows strongest differential methylation represented by 12 hypermethylated promoter CpGs (red 
arrow). f Persistent hypermethylation of 25 gene promoters. Venn diagram depicts hypermethylated gene promoters with > 3 hypermethylated 
promoter probes 17 and 24 days after targeting the HER2 promoter with Ezh2-dCas9 + D3A-dCas9 + D3L. g RT-qPCR at potential off-target sites 
23 days after treatment with indicated epi-dCas9. As a control, HER2 expression was knocked down by HER2 siRNA and compared to siRNA control 
treatment. Expression levels were calculated relative to GAPDH (Tuckey’s test, ***P < 0.001; n = 3; mean ± SEM)
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we observed very few off-target H3K27ac changes in the 
genome of the transfected cells and did not observe any 
changes in gene expression at the off-target loci tested.
Global analysis of persistent DNA methylation 
after combinatorial targeting with Ezh2‑dCas9 
or KRAB‑dCas9 and DNA methyltransferase (D3A‑dCas9 
and D3L)
We have demonstrated that treatment with Ezh2-dCas9, 
plus D3A-dCas9 and DNMT3L, cannot only establish, 
but also stably maintain DNA methylation (Fig.  1d, e). 
Some groups have reported very precise targeted meth-
ylation [25, 42, 43], and others have found significant 
amounts of off-target methylation [43–45]. We used the 
Illumina Infinium HumanMethylationEPIC (EPIC) array 
to obtain a global view of DNA methylation at human 
promoters. Global DNA methylation was analyzed 
17  days after cells were treated with HER2 gRNAs and 
Ezh2-dCas9 or KRAB-dCas9 cocktails (containing D3A-
dCas9 + D3L) and compared to cells transfected with 
dCas9 (no effector domain); biological replicates showed 
strong bivariate correlation (R2 > 0.99; Additional file  8: 
Figure S6). Methylation levels are recorded as beta val-
ues (β), which are determined by the ratio of intensities 
between methylated (M) and unmethylated (U) alleles 
(β = M/M + U). EPIC arrays reliably detect a change 
in beta values of 0.2 (methylation change of 20%) with 
FDR < 0.01. Since hypermethylation of gene promoters 
is frequently associated with transcriptional repression, 
average methylation was calculated at promoter regions 
encompassing from 1.5 kb upstream of the transcription 
start site (TSS) through the 5′ UTR. On average, each 
promoter region is represented by 14 CpG probes on 
the EPIC array. Promoter CpGs showing a 20% increase 
in DNA methylation are highlighted in Fig.  3d regard-
less of the original promoter methylation state. Differen-
tially methylated regions (DMRs) usually involve adjacent 
CpGs or a group of CpGs close together that have differ-
ent methylation patterns between samples, with a mini-
mum requirement of > 3 differentially methylated CpGs 
[46, 47]. We determined the frequency of methylated 
CpGs occurring at each promoter region and observed 
that the majority of promoter regions only contained a 
single hypermethylated CpG after transfection with the 
epi-dCas9 fusions (Fig. 3e). For example, KRAB-dCas9 in 
combination with D3A-dCas9 and D3L resulted in hyper-
methylation of 223 CpGs corresponding to 199 genes 
(GenCode Basic v12). 91% of these genes contained only 
a single hypermethylated CpG in the entire promoter 
region (Additional file 9: Table S3). Only one possible off-
target gene with > 3 hypermethylated promoter CpGs was 
identified. The SHOX2 gene promoter contains 4 hyper-
methylated CpGs with an average methylation of 33% 
as compared to 6% in dCas9 control cells. We note that 
the KRAB-dCas9 plus D3A-dCas9 and D3L treated cells 
were only transiently exposed to DNA methyltransferase. 
Our results demonstrate that hit-and-run DNA methyl-
transferase targeting does not display promiscuous off-
target activity under these experimental conditions.
Ezh2-dCas9 treatment in combination with D3A-
dCas9 and D3L resulted in hypermethylation of more 
CpG probes (2966) than the KRAB-dCas9 experiment. 
However, even in this case, only 51 promoters con-
tained > 3 hypermethylated CpGs (Additional file  9: 
Table S3). Importantly, the targeted HER2 promoter con-
tained the most hypermethylated CpGs (12 hypermeth-
ylated CpGs), showing an average methylation of 48% as 
compared to 7% in dCas9 control samples.
It has previously been reported that gain of off-target 
methylation by transient overexpression of DNMT3A-
dCas9 fusions is of a transient nature [45, 48]. We wanted 
to determine whether promoter hypermethylation was 
stabilized 17 days after combinatorial Ezh2-dCas9 treat-
ment with D3A-dCas9/D3L. DNA methylation 24  days 
after transfection showed high concordance (93%) with 
1876 overlapping hypermethylated CpGs at 17 and 
24  days after transfection with 2966 and 2018 hyper-
methylated CpGs, respectively. We then compared the 89 
off-target sites predicted by Cas-OFFinder (as described 
earlier; Additional file  2: Table  S1) to the 1876 overlap-
ping hypermethylated CpGs. It is possible that a hyper-
methylated CpG is not directly within, but adjacent to 
a predicted off-target site. We therefore expanded the 
hypermethylated region by the length of a nucleosome 
up- and downstream of the CpG (± 146 base pairs). There 
were no overlaps between predicted off-target sites and 
the expanded hypermethylated regions. Using the crite-
ria of > 3 hypermethylated CpGs per gene promoter, half 
of the gene promoters we identified to be hypermethyl-
ated at 17 days post-transfection were still hypermethyl-
ated at 24 day post-transfection (Fig. 3f; Additional file 9: 
Table  S3). Among the 25 persistently hypermethylated 
gene promoters (represented by 132 CpG probes), HER2 
still ranked highest having 12 hypermethylated CpGs and 
an average methylation level of 46%. SHOX2, which was 
the only potential off-target identified by D3A-dCas9/
D3L treatment with KRAB-dCas9, was also among the 
25 persistently hypermethylated gene promoters. To 
evaluate the impact of DNA methylation on expression of 
potential off-target sites, we performed RT-qPCR in cells 
23 days after co-transfection with the Ezh2-dCas9 cock-
tail (plus D3A-dCas9/D3L) and compared expression to 
control cells treated with dCas9 without effector domain 
(Fig.  3g). To evaluate possible downstream effects of 
HER2 repression, HCT116 cells with siRNA mediated 
knockdown of HER2 were used as a control. SHOX2 
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and MPP1 encompassed 9 and 4 hypermethylated CpG 
probes, respectively. Neither SHOX2 nor MPP1 showed 
changes in gene expression when compared to control 
samples, while HER2 was robustly downregulated in cells 
treated with HER2 siRNA and in cells 23 days after treat-
ment with Ezh2-dCas9 cocktail (Fig. 3g).
We further hypothesized that true off-targets from 
combinatorial Ezh2-dCas9/DNMT3A-dCas9 and D3L 
treatment would contain both an increase in DNA meth-
ylation and a decrease in H3K27 acetylation. When we 
overlapped the 25 hypermethylated CpG probes iden-
tified at 24  days after transfection with H3K27ac ChIP 
peaks that showed reduced binding in Ezh2-dCas9/D3A-
dCas9/D3L treated cells, only the target gene HER2 was 
identified. Taken together, our data demonstrate that the 
Ezh2-dCas9 cocktail can engineer epigenetic memory 
at the HER2 locus conferring long-term repression with 
very few potential off-targets. Persistent repression is 
associated with a stably maintained epigenetic switch to 
a heterochromatin environment stably marked by both, 
histone H3K27 trimethylation and DNA methylation.
Alternative strategies for combinatorial epi‑dCas9 
recruitment while maintaining a reduced number of gRNAs
Global ChIP-seq and DNA methylation analysis revealed 
very few potential off-target sites. However, the use of 
multiple gRNAs constitutes an increased risk for off-
target binding of epi-dCas9 fusions. Since a combina-
tion of different epi-dCas9 fusions is required to engineer 
persistent epigenetic silencing, we explored alternative 
recruitment strategies that will allow us to recruit mul-
tiple epi-dCas9 fusions while maintaining a reduced 
number of gRNAs. First, we explored whether a single 
gRNA could facilitate targeted epigenetic silencing with 
multiple epi-dCas9 fusions. Multiple epi-dCas9 fusions 
are exploiting the same gRNA, possibly leading to DNA 
binding competition. To test this, we used two epi-dCas9 
fusions (KRAB-dCas9 and D3A-dCas9) in combination 
with D3L, with a pool of three gRNAs or a single gRNA 
targeting the Snurf promoter in Neuro2A cells. Surpris-
ingly, we found that a single gRNA was just as effective as 
the gRNA pool in inducing long-term repression. Snurf 
gRNA 1 induced 2.3-fold repression, while the gRNA 
pool (gRNAs 1,2 and 3) resulted in 1.6-fold repression of 
Snurf expression (Additional file 10: Figure S7A).
Alternatively, recruitment of effector domains through 
the gRNA component may offer a solution to increas-
ing the number of epi-dCas9 fusions while reducing the 
number of gRNAs and therefore the number of possible 
off-target sites (Additional file 10: Figure S7B). In previ-
ous studies, gRNA scaffolds were used that contain two 
MS2 aptamers (MS2-gRNA), one in the gRNA tetraloop 
and one in stem loop 2. These aptamers can be recog-
nized by the MS2 bacteriophage coat protein (MCP), to 
which various effector domains (VP64, P65, P65-HSF1, 
SS18 or HP1) can be attached [33, 49–52]. For our study, 
we first created fusions of KRAB and Ezh2 to either one 
or a tandem array of two MCPs, resulting in either 1x or 
2x MCP-effector fusions. MS2-gRNAs were designed to 
target the same endogenous sites as their respective tra-
ditional gRNAs. When dCas9 was targeted to the HER2 
promoter by a pool of three MS2-gRNAs, 2xMCP-KRAB 
showed twofold repression at 4  days post-transfection 
in HCT116 cells, while 1xMCP-KRAB was not able to 
repress HER2 expression. We then determined whether 
effector pairing of epi-dCas9 and MCP fusions could 
increase the repressive capacity of gRNA-based recruit-
ment. Simultaneous recruitment of KRAB-dCas9 and 
2xMCP-KRAB decreased repression to 1.3-fold, perhaps 
by destabilizing the dCas9 complex. However, the direct 
fusion of KRAB to the N-terminus of dCas9 (KRAB-
dCas9) was most effective resulting in tenfold repres-
sion of HER2 expression. 1xMCP-Ezh2 and 2xMCP-Ezh2 
fusions were unable to repress HER2 gene expression. We 
additionally performed this test at the Snurf promoter in 
Neuro2A cells. Again, only the direct fusion of KRAB-
dCas9 was able to persistently repress Snurf expression, 
while one or two MS2-gRNAs recruiting 2xMCP-KRAB 
to the dCas9 complex did not cause significant long-term 
repression (Additional file  10: Figure S7B). While the 
MS2-gRNA recruitment strategy holds great potential, 
direct epi-dCas9 fusions in combination with a single-
gRNA induced persistent epigenetic silencing more effi-
ciently under these conditions.
Co‑targeting of full‑length DNMT3L is necessary 
and sufficient to enable persistent gene silencing 
by Ezh2‑dCas9
The catalytic activity of the de novo DNA methyl trans-
ferase DNMT3A is enhanced by dimerization with 
DNMT3L [28]. In fact, a direct fusion of the C-terminal 
portion of DNMT3L to the catalytic domain of Dnmt3a 
(D3a3L) to a DNA targeting module (zinc finger protein 
or dCas9) enabled efficient DNA methylation at endog-
enous target sites [29, 42, 53]. We have shown that the 
D3A-based recruitment approach can initiate long-term 
repression in the presence of overexpressed DNMT3L 
(Fig.  4a). Alternatively, we sought to explore the impact 
of a targetable version of DNMT3L on long-term silenc-
ing by co-targeting D3A-dCas9 and targetable DNMT3L 
(D3L) fusions (Fig. 4b). In order to avoid overexpression 
of the catalytically active DNMT3A, we tested the abil-
ity of targetable D3L fusions to recruit endogenous D3A 
activity (D3L-based recruitment; Fig. 4c).
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Although the C terminus of DNMT3L is able to dimer-
ize with DNMT3A, we hypothesized that the ADD 
domain located in the N-terminal portion also plays an 
important role. Therefore full-length DNMT3L (D3L) 
was fused to either the N or the C terminus of dCas9 
resulting in D3L-dCas9 and dCas9-D3L, respectively 
(Fig.  4d). Overexpression of DNMT3L in addition to 
KRAB-dCas9 and D3A-dCas9 yielded the strongest long-
term repression (2.7-fold) at the Snurf promoter in Neu-
ro2A cells (Fig.  4a). The combination of KRAB-dCas9 
with dCas9-D3a3L resulted in long-term repression, 
but at a reduced level (1.4-fold) (Fig.  4a). Comparable 
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Fig. 4 Full-length DNMT3L is required and sufficient to establish long-term repression facilitated by KRAB-dCas9 and Ezh2-dCas9. Long-term 
repression was evaluated using three different approaches for targeted DNA methylation: a D3A-based recruitment (D3A-dCas9 + overexpressed 
D3L), b Co-targeting of D3A + D3L (D3A-dCas9 + dCas9-D3L) and c D3L-based recruitment (dCas9-D3L). a Comparison of the D3A-based 
recruitment approach with the targetable D3a3L fusion (dCas9-D3a3L), HER2 mRNA levels in HCT116 cells and Snurf mRNA levels in Neuro2A cells 
were determined by RT-qPCR 14 days after co-transfection of plasmids expressing the indicated epi-dCas9 fusions with the three gRNAs targeted 
to the HER2 or Snurf promoter (Dunnett’s test, *P < 0.05, **P < 0.01, ***P < 0.001; n = 3; mean ± SEM). b Long-term repression by co-targeting D3A 
and D3L fusions. Performance of D3L fusions to the N or C terminus of dCas9 was compared. HER2 mRNA levels in HCT116 cells and Snurf mRNA 
levels in Neuro2A cells were determined by RT-qPCR 14 days after co-transfection of plasmids expressing the indicated epi-dCas9 fusions with the 
three gRNAs targeted to the Snurf or HER2 promoter (Dunnett’s test, *P < 0.05, **P < 0.01, ***P < 0.001; n = 3; mean ± SEM). c Long-term repression 
was evaluated by RT-qPCR 14 days after co-transfection of dCas9-DNMT3L with KRAB-dCas9 or Ezh2-dCas9 with gRNAs targeted to the SNURF 
and HER2 promoter in LNCaP cells. Expression levels were compared to dCas9 with no ED (Dunnett’s test, *P < 0.05, **P < 0.01, ***P < 0.001; n = 3; 
mean ± SEM). d Schematic of overexpressed full-length DNMT3L and design of dCas9 fusions. DNMT3A or DNMT3L were fused to the N-terminus 
of dCas9 (D3A-dCas9 and D3L-dCas9, respectively) or the C terminus of dCas9 (dCas9-D3L). dCas9-D3a3L contains D3a and the C-terminal 
portion of D3L (D3a3L) fused to the N-terminus of dCas9. e Average methylation levels were determined by bisulfite cloning (left panel) and 
high-throughput bisulfite amplicon sequencing (right panel) at the HER2 promoter 10 days after transfection with the indicated Ezh2-dCas9 and 
KRAB-dCas9 cocktails or dCas9 (no effector domain). Methylation after treatment with only dCas9-D3L and three HER2 gRNAs was also evaluated. 
Bisulfite cloning results are displayed as lollipop plots. Each line represents a single clone, filled and empty circles represent a single methylated or 
unmethylated CpG, respectively. Analysis of bisulfite amplicons sequencing was performed from two biological replicates. Average % methylation 
is plotted for each indicated epi-dCas9 treatment. Methylation obtained with targetable dCas9-D3L (orange bars) was compared with methylation 
status after combinatorial KRAB-dCas9 (K) and Ezh2-dCas9 (E) with D3A-dCas9 (D3A) and overexpressed D3L (gray bars). All treatments resulted in 
significant HER2 target methylation when compared to cells treated with dCas9 or cells that were not transfetcted (NT) (Dunnett’s test, ***P < 0.001; 
n = 2; mean ± SEM)
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repression (1.5-fold) was obtained when KRAB-dCas9 
was combined with D3A-dCas9 and targetable DNMT3L 
fusions (D3L-dCas9 and dCas9-D3L; Fig.  4b). Ezh2-
dCas9 also showed the strongest Snurf repression (three-
fold) when added with D3A-dCas9 and overexpressed 
D3L. On the other hand, Ezh2-dCas9 did not show any 
long-term repression when accompanied by dCas9-
D3a3L or the combination of D3A-dCas9 and D3L-dCas9 
(N-terminal D3L fusion). Thus, dCas9-D3L (C-terminal 
D3L fusion) was the only targetable version of DNMT3L 
capable of inducing long-term Snurf repression (1.8-
fold) in combination with Ezh2-dCas9 and D3A-dCas9 
(Fig. 4b). The same trend was observed at the HER2 locus 
in HCT116 cells. Ezh2-dCas9 and D3A-dCas9 were only 
able to persistently repress HER2 expression when com-
bined with D3L overexpression or with the targetable 
C-terminal version dCas9-D3L (1.6 or 1.4-fold, respec-
tively). Both the addition of dCas9-D3a3L and the com-
bination of D3A-dCas9 with N-terminal D3L-dCas9 
were not able to induce long-term repression, suggest-
ing that full-length DNMT3L is necessary for long-term 
repression by Ezh2-dCas9 and D3A-dCas9, either due to 
recruitment of protein partners or to effects on activity 
due to conformational differences between the different 
constructs.
Overexpression of targetable DNA methyltransferase 
DNMT3A has recently raised concerns about off-target 
DNA methylation. The enzymatic activity of DNMT3A 
is enhanced by its dimerization partner DNMT3L, which 
does not display catalytic activity by itself. So far, we have 
introduced D3L by overexpression or by co-targeting 
with dCas9-D3L (Fig.  4a, b). We hypothesized that tar-
geting of dCas9-D3L to an endogenous promoter is suf-
ficient for recruitment of endogenous D3A to stably 
repress the target locus. To test this hypothesis, we co-
transfected LNCaP cells with a combination of dCas9-
D3L and either KRAB-dCas9 or Ezh2-dCas9 together 
with a gRNA pool targeted to the SNURF and HER2 pro-
moters. Long-term repression was determined 14  days 
after transfection and compared to dCas9 with no effec-
tor. Significant long-term repression was observed with 
dCas9-D3L and either KRAB-dCas9 or Ezh2-dCas9 
with 1.8- or 1.3-fold repression of SNURF expression, 
respectively and 2.5- or twofold of HER2 expression, 
respectively (Fig. 4c). We performed bisulfite sequencing 
to determine the methylation status achieved with the 
D3L-based recruitment approach at the HER2 promoter 
(Fig.  4e). To directly compare this approach to the pre-
viously applied combinatorial treatment of KRAB-dCas9 
or Ezh2-dCas9 with D3A-dCas9 and overexpressed D3L 
(Fig. 1d), we collected HER2− cells by FACS 4 days after 
co-transfection with three gRNAs targeting the HER2 
promoter in HCT116 cells. HER2− cells were expanded 
until sufficient amounts were available for bisulfite 
sequencing (10  days). Co-targeting of KRAB-dCas9, 
D3A-dCas9 and dCas9-D3L resulted in 22% methyla-
tion, while combinatorial treatment of KRAB-dCas9/
D3A-dCas9 with overexpressed D3L increased methyla-
tion to 46%. When D3A-dCas9 was omitted, combina-
torial treatment of KRAB-dCas9 or Ezh2-dCas9 with 
dCas9-D3L resulted in an average methylation of 20% 
and 29%, respectively (Fig. 4e). Surprisingly, comparable 
methylation levels (20%) were reached when dCas9-D3L 
itself was targeted to the HER2 promoter. The HER2 pro-
moter region was unmethylated in the untreated control 
and in cells treated with dCas9 (no effector domain). Co-
targeting of KRAB-dCas9, D3A-dCas9 and dCas9-D3L to 
the HER2 promoter resulted in low levels of methylation 
(9%) suggesting that this approach is less efficient, which 
is also reflected in lower repressive ability (Fig. 4b).
Long-term repression facilitated by dCas9-D3L is 
advantageous for two reasons; (1) co-targeting requires 
only one epi-dCas9 (D3L fusion) instead of two compo-
nents (D3A-dCas9 plus dCas9-D3L) for efficient long-
term repression and (2) co-targeting with dCas9-D3L 
avoids overexpression of enzymatically active D3A and 
may therefore offer another strategy to limit off-target 
effects.
Discussion
Although a variety of gene targeting tools exist that can 
robustly alter transcriptional activity for a short period, 
there is currently not a single tool or combination of 
tools that can universally invoke persistent epigenetic 
silencing of any desired gene in a predictable manner. 
There is a need for alternative hit-and-run epigenome 
editing tools that have a lasting effect in cells with only 
transient exposure to the tool itself. In this study, we 
observed that combinatorial treatment with Ezh2-dCas9 
and DNA methylation (D3A-dCas9 and overexpressed 
D3L) was able to initiate long-term repression at two 
genomic loci (SNURF, HER2) in four different cell types. 
Although combinatorial KRAB-dCas9 treatment with 
D3A-dCas9 and overexpressed D3L was able to initi-
ate long-term repression at most target genes tested, 
it failed to maintain persistence at HER2 in HCT116 
cells. We found that combinatorial KRAB-dCas9 treat-
ment (KRAB + D3A + D3L), triggered a strong burst 
in H3K9me3 at the target locus, but the repressive 
H3K9me3 mark was completely lost at 24  days after 
treatment. The loss of H3K9me3 goes hand in hand with 
maintained hypermethylation of only one CpG probe in 
the HER2 promoter, which was not sufficient for persis-
tence and resulted in re-activation of HER2 gene expres-
sion. On the other hand, combinatorial Ezh2-dCas9 
treatment (Ezh2 + D3A + D3L) led to the establishment 
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and maintenance of a repressive chromatin environment 
and long-term HER2 repression. Both histone meth-
ylation (H3K27me3) and DNA methylation marks were 
maintained through approximately 57 cell divisions. 
DNA methylation did not stay restricted to the promoter 
region targeted by HER2 gRNAs, but expanded to the 
adjacent CpG island covering a total of 1.25 kb.
Individual dCas9 fusions with epigenetic effector 
domains were in general not efficient in establishing epi-
genetic memory. There were a few exceptions that might 
have been cell type or locus specific. Similarly, Ezh2-
dCas9 was only able to induce long-term repression in 
combination with D3A-dCas9 and D3L. In fact, we found 
that full-length D3L is required for Ezh2-dCas9 medi-
ated long-term repression. The epi-dCas9 fusion with 
a hybrid methyltransferase containing a direct fusion 
of the C-terminal portion of DNMT3L to the catalytic 
domain of Dnmt3a (D3a3L; [53]) was unable to establish 
long-term epigenetic memory. Our data suggest that the 
N-terminus of DNMT3L containing the ADD domain, 
which interacts with the unmodified histone H3 tail [54], 
is important for establishing this interaction; the 3a3L 
fusion lacks this domain. Since the dCas9-D3a3L fusion 
is effective in DNA methylation, we hypothesize that 
DNA and histone methylation alone are not sufficient for 
long-term repression, but that the interaction between 
Ezh2 and DNMT3A/DNMT3L itself is important for 
establishment and maintenance of epigenetic memory. 
Ezh2 as well as EED have been shown to directly inter-
act with DNMT3A. The N-terminal portion of Ezh2 has 
been shown to directly interact with the de novo DNA 
methyltransferases DNMT3A and DNMT3B and with 
the maintenance methyltransferase DNMT1.
Why might the establishment and inheritance of 
repressive chromatin states require both histone and 
DNA methyltransferases? In nature, a positive feedback 
loop between H3 lysine 9 (H3K9) methylation and DNA 
methylation has been well established and is a character-
istic hallmark of mammalian heterochromatin [55–57]. 
Crosstalk between DNA methylation and H3K9 meth-
ylation is facilitated by the methyl-CpG-binding domain 
protein (MeCP2) as well as by heterochromatin protein 
1 (HP1) [55, 57]. Heterochromatin marked by H3K9me3 
and 5mC is bound by the KAP1/SETDB1(ESET) co-
repressor complex, which is recruited by the Krueppel-
associated box (KRAB) domain [18, 19]. Either DNA 
de-methylation or knockdown of KAP1 or SETDB1 lead 
to loss of DNA and H3K9 methylation and are accompa-
nied by transcriptional derepression [58, 59]. The inter-
play between H3K27me3 and DNA methylation is less 
obvious, but nonetheless important for cell development 
and cellular identity. Unlike H3K9me3, H3K27me3 and 
DNA methylation are mutually exclusive marks at many 
genomic regions with high CpG density. However, a sub-
set of promoter regions including bivalent gene promot-
ers demonstrate crosstalk between H3K27me3 and DNA 
methylation [60]. Bivalent domains are found at pro-
moters of developmentally regulated genes in stem cells 
and carry histone marks for both active and repressed 
chromatin (H3K4me3 and H3K27me3, respectively). 
Bivalently marked genes are silenced in undifferentiated 
stem cells, but considered poised for expression upon 
developmental cues [61]. Interestingly, H3K27me3 was 
reduced at nearly all bivalent promoters in mouse embry-
onic stem cells lacking DNA methyltransferases [60, 62–
64]. Lower H3K27me3 occupancy was accompanied by 
reduced presence of PRC2 complex members Ezh2 and 
Suz12 [62, 63]. Effects on H3K27me3 were not only con-
ferred by 5mC, but were also dependent on interactions 
with enzymatically active DNMT proteins (DNMT1, 
DNMT3A and DNMT3B; [65]. It has been proposed that 
DNA methylation at H3K27me3 marked regions leads to 
persistent gene repression and that this epigenetic mem-
ory may require interaction between the H3K27 methyl-
transferase EZH2 and DNA methyltransferase DNMT3A 
[65]. These studies indicate that DNA methylation plays 
an important role in the maintenance of normal pro-
moter H3K27me3 patterns in a context-specific manner.
A general concern regarding off-target activity has 
been raised regarding using the active Cas9 nuclease 
for possible corrective treatment in human cells. Such 
off-target effects cause permanent changes to the DNA 
sequence. However, careful titration of Cas9 protein, pro-
tein engineering and careful design of gRNAs have given 
Cas9 the ability to function as a precise genome editing 
tool [66, 67]. Recently, concerns have been raised regard-
ing dCas9-based epigenome editing (epi-dCas9) tools. 
Several reports have demonstrated high specificity of 
dCas9-KRAB [22, 68] and dCas9-DNMT3A [25]. How-
ever, some studies have demonstrated off-target activity 
of dCas9 fusions with DNMT3A [42, 43, 45]. Hypermeth-
ylation at single CpGs may, in fact, be genuine off-target 
events since they are reproducibly found in biological 
replicates. Notably, we do not observe robust off-target 
methylation under our experimental conditions. Differ-
ences in these studies can most likely be explained by the 
different experimental designs. Similar to Cas9 whose 
off-target cleavage activity increased with the amount of 
Cas9 enzyme present, off-target methylation is depend-
ent on the dCas9-DNMT3A/3B concentration [43, 45]. 
Furthermore, we have demonstrated that dCas9-D3L is 
sufficient to initiate long-term silencing by Ezh2-dCas9 
or KRAB-dCas9. We also found that targeting D3L alone 
can methylate the HER2 locus, but the implications for 
long-term silencing and spreading of DNA methyla-
tion have not yet been explored. These findings suggest 
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that targeting dCas9-D3L, which lacks enzymatic activ-
ity itself, recruits endogenous DNA methyltransferase 
DNMT3A. This may offer an advantage compared to 
overexpression of an active enzyme (D3A) in limiting off-
target activity. On the other hand, overexpression of D3L 
may act as a sponge for endogenous D3A, potentially 
causing misregulation by hypomethylation of off-target 
genes. Future studies should carefully examine these 
possibilities.
We then explored two strategies that would allow 
recruitment of multiple epi-dCas9 fusions, while limit-
ing the number of gRNAs in order to reduce potential 
off-target sites. Surprisingly, we found that a single gRNA 
induced persistent silencing as well as a pool of 3 gRNA 
when targeting two different epi-dCas9 effectors (KRAB-
dCas9/D3A-dCas9 plus D3L) to the Snurf promoter. 
Similar observations have been reported [25] but only for 
a subset of gRNAs. They reported that a pool of gRNA 
was as good or better than individual gRNAs when co-
targeting multiple epi-dCas9 fusions. Therefore, we don’t 
expect that this observation is generalizable to any gRNA, 
but it does mean that different epi-dCas9 molecules can 
interact dynamically through a single gRNA or that dif-
ferent epi-dCas9 s aggregate through gRNA independent 
interactions. We also tested RNA-mediated recruitment 
of epigenetic repressor domains to increase the combina-
torial capacity of the epi-dCas9 system while maintain-
ing a reduced number of gRNAs. However, recruitment 
of MCP-Ezh2 by MS2 stem loop-containing gRNAs did 
not result in repression of the target locus. It is possible 
that the relatively large size of Ezh2 (85 kDa) destabilizes 
the dCas9 complex with the target site. MCP-KRAB was 
able to repress the target locus, but with less efficiency 
than the direct dCas9-KRAB fusion. It is possible that 
the altered structure of the MS2-gRNAs, as compared to 
standard gRNAs, results in reduced recruitment of dCas9 
or less stable dCas9/target interactions, leading to lower 
repressive capacity. However, we do note that the MS2-
based recruitment approach has worked quite efficiently 
for gene activation [33, 49–52]. Therefore, it is possible 
that different experimental parameters could lead to 
stronger repressive capacity using this system.
There has been a significant effort to determine fea-
tures that make a specific genomic site amenable to 
cleavage by the RNA-guided nuclease Cas9. There is 
some evidence for sequence-specific context [69], but, 
more importantly, cleavage by Cas9 is significantly 
inhibited by nucleosomes in  vivo [70–72]. The field of 
epigenome editing faces similar challenges that can only 
partially be explained by sequence features or the pres-
ence of nucleosomes. Since most epi-dCas9 fusions are 
targeted to DNase hypersensitivity sites, the variation 
of success must arise from other features. The effect of 
targeted epigenetic reprograming might be influenced 
by factors such as epigenetic marks, three-dimensional 
interactions (e.g., between a promoter and an enhancer, 
or localization of the DNA region to a subnuclear com-
partment such as a transcriptional factory), and initial 
expression levels, which may be locus and cell-type 
dependent. A systematic study encompassing a large 
set of loci is needed to identify determinants that make 
a locus amenable to engineering persistent silencing to 
ensure more predictable outcomes. In addition, engi-
neering epigenetic memory may depend on cellular fac-
tors that vary in different cell types. Some differences 
may be related to the use of dividing versus non-divid-
ing cells [25, 42], more studies are needed to establish 
guidelines that can predict which combination of tar-
getable epigenetic effectors can establish and maintain 
an epigenetic switch at any desired locus and cell type.
It should be possible to treat epigenetic disorders by 
altering the epigenetic information at specific loci. To 
avoid the need for lifelong expression of an exogenous 
modifier protein, it is critical to establish a persistent 
epigenetic state, as seen in nature. However, there is 
currently no single or combination of epigenetic tar-
geting tools that can induce epigenetic memory at any 
desired locus in any cell type which targeting cock-
tail is most efficient is cell type dependent, revealing a 
not yet understood cell-specific context for establish-
ment of epigenetic memory [25, 26, 42]. Although an 
epi-dCas9 cocktail containing KRAB, DNMT3A, and 
DNMT3L was able to repress endogenous genes to 
various degrees (BM2, IFNAR1 and VEGFA) [25], the 
same cocktail was unable to maintain repression at the 
HER2 locus in HCT116 cells [26]. Targeted DNA meth-
ylation facilitated through use of only DNMT3A has 
shown modest long-term repression in some but not 
all reporter cell lines tested [25, 73]. Similarly, a dCas9 
fusion with DNMT3A-DNMT3L was able to induce 
long-term repression at some, but not all, targeted 
genes in primary myoepithelial cells [42]. Although 
many writers and readers of histone modifications have 
been identified (reviewed in [8]), it remains an open 
question how they collaborate to establish genome-
wide chromatin patterns and epigenetic memory in dif-
ferent chromatin and cellular contexts.
Conclusions
Epigenetic changes in nature are associated with long-
term activation or silencing of gene transcription. With 
the ability to target such changes in epigenetic informa-
tion, it should be possible to achieve the same long-term 
effects as are observed in nature. However, the observed 
effects of epigenetic editing are often of limited magni-
tude and duration. One hypothesis is that there is a lack 
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of sufficient understanding of the initial epigenetic state 
of the target gene, and how that specific state is affected 
by the editing tools. The work reported here demon-
strates (a) a clear difference between the histone meth-
yltransferase requirements for short- and long-term 
silencing, and (b) that those requirements can be differ-
ent for different target genes. These results represent a 
significant expansion beyond the prevailing paradigm 
that persistent silencing can be best achieved by a com-
bination of KRAB, DNMT3A and DNMT3L [25]. Further 
studies are needed to obtain a more detailed understand-
ing of the mechanisms underlying these observed dif-
ferences and to enable predictable targeted control of 
epigenetic effects at individual loci that are similar to 
those observed in nature.
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